Biotech firm to use Merck’s CRISPR patents in rodent models
France-based biotechnology company genOway has acquired the exclusive global rights to German pharmaceutical company Merck Group’s CRISPR patents, to be used in the production and sale of rodent models.
Merck announced the strategic alliance on Monday, December 10.
The German company has 14 years’ experience of genome editing, while genOway specialises in creating customised, genetically modified mice, rat, and cell models for use in research.
Both companies have already identified research fields where they can combine their respective technologies and expertise to create and validate new CRISPR/Cas9-related products and services.
Through the deal, Merck’s patented CRISPR integration technology will be used to develop new solutions which will accelerate drug delivery, according to the announcement.
Udit Batra, CEO, life science, and member of Merck’s executive board, said: “Together with genOway, we will get the best research models out to the pharmaceutical and biotech industries as well as academic laboratories quickly, so we can help accelerate their research, shorten drug development timelines and treat previously untreatable diseases in faster and more targeted ways.”
The agreement also allows genOway to develop a network of sublicensees in the model creation and distribution business, as well as in preclinical services, for all potential applications of the patents worldwide. Merck said there will be a “strong focus” in the US, Europe, and Asia.
Alexandre Fraichard, CEO of genOway, said: “The CRISPR/Cas9 IP landscape has been complex and uncertain over the last years. The situation has changed and the Merck IP portfolio is clearly central to CRISPR/Cas9-based eukaryotic genome-editing applications.
“This alliance, combining research and business, will enable us to provide the scientific community with more physiologically relevant models and the necessary IP rights which will ultimately speed delivering better drugs to patients.”
Merck noted that animal welfare is one of its highest priorities, and the company only conducts animal research activities if there is no other method of testing available. The German company has an external Bioethics Advisory Panel which advises on the ethical and legal implications of genome editing research.
Batra said: “We will continue to play an active role, responsibly and ethically, in ensuring that scientists have access to the latest CRISPR technologies.”
Financial details of the agreement have not been disclosed.
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
